Communiqués Lexeo Therapeutics, Inc.

Actions

LXEO

US52886X1072

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 06/10/2026			Varia. 5j.	Varia. 1 janv.
3,300 ^USD	-3,23%		-3,51%	-66,77%

22/09	Transcript : Lexeo Therapeutics, Inc., Mantle Therapeutics Inc. - M&A Call
22/09	Lexeo Therapeutics va acquérir Mantle Therapeutics pour un montant pouvant atteindre 21,3 millions de dollars ; conclut trois collaborations de recherche	MT

Communiqués

01/10	Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)	AQ
23/09	Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum	AQ
22/09	Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia	AQ
02/09	Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September	AQ
12/08	Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights	AQ
05/08	Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy	AQ
17/06	Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia	AQ
15/06	Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia	AQ
19/05	Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference	AQ
11/05	Lexeo Therapeutics : Corporate PresentationvMay2026	PU
11/05	Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights	AQ
27/04	Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting	AQ
30/03	Lexeo Therapeutics : Corporate Presentation March 2026	PU
30/03	Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights	AQ
03/03	Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference	AQ
05/02	Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February	AQ
27/01	Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics	AQ
12/01	Lexeo Therapeutics : JAN12 2026 LX2020 Interim Clinical Data vF	PU
12/01	Lexeo Therapeutics : Corporate Presentation J.P. Morgan Healthcare Conference January 2026	PU
12/01	Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy	AQ
08/01	Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy	AQ
22/12	Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
04/12	Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum	AQ
06/11	Lexeo Therapeutics : Corporate Presentation November 2025	PU
05/11	Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights	AQ